EN DE
Watch Cellebrite DI for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cellebrite DI (CLBT) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Cellebrite DI stock $13.34, price $12.45, upside +7.2%, quality 63 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Technology US · Home Israel · ISIN IL0011794802

CD Cellebrite DI logo Some data Nov 3, 2026

Cellebrite DI

CLBT · US
Fairly valued, in a downtrend

The stock costs about what our calculation considers fair.

Quality 63/100
Healthy Growth (revenue 5y +19.5 %/yr in USD)
Solidly profitable · 11.4% net margin (TTM)
Generates free cash flow
Upbeat coverage
Revenue last quarter +16% vs. a year ago.
Fair value $13.34 · Fairly valued
Mixed vs. peers (6/12)
Moderate moat 51/100 · thin data
Insiders sold $5.1M (6M)
Some data
Quality growth
Watch Cellebrite DI for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$26.00 $3.92 Fair Value $13.34 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range $3.92 – $26.00 · fair‑value band $9.34 – $17.35 · the $12.45 price screens below the $13.34 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow Cellebrite DI in your weekly email

Every Wednesday you see whether Cellebrite DI is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific.

Show moreShow less

The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency.

It also offers Inseyets, digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations; Guardian Forensics, an evidence management solution which enables customers to manage their digital forensics workflows, and to store, share and review digital evidence; Guardian Collaborate, a digital evidence sharing tool; and Guardian Investigate, a case management and AI-powered analytics solution.

In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence and enables actionable insights into a range of crime types; Corellium Falcon for conducting mobile vulnerability research, exploit introspection, and malware analysis; and Corellium Viper for mobile application penetration testing capabilities.

Further, the company offers professional services, such as training and certification services, and advanced services. It serves federal, state, and local agencies, as well as corporations and service providers. The company is headquartered in Petah Tikva, Israel.

Stock analysis

Cellebrite DI (CLBT) currently trades at $12.45, while our model-based Fair Value estimate is $13.34, so the stock looks roughly fairly valued today (gap 6.7%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $12.95 per share, and 6 of the 24 models we run sit above the $12.45 price.

Bear case: the Economic Profit group reads lowest at $3.05, and 18 of the 24 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $9.34 (bear) to $17.35 (bull), the price of $12.45 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 63/100 (solid quality), in the Technology sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Cellebrite DI reported revenue of $476M in FY2025 versus $246M in FY2021, a compound +17.9%/yr. Reported net income was $78.3M in FY2025, compounding +2.3%/yr from FY2021.

Key figures

Market cap $3.1B Mid · P/E ratio 54.1 · P/S ratio 6.12 · EPS (TTM) $0.2300 · Net margin 11.4% · Return on equity 12.4% · Return on assets (EBIT) 5.2% (5-year average) · Operating margin 5.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 35% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Technology peers we cover trades at −11% fair-value upside, at 7%, CLBT screens cheaper than that median.

Fair Value models

Bear $9.34 Fair Value $13.34 Bull $17.35
Price $12.45 · Upside +7.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.1972 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $9.10 $14.53 $28.98 74
Growth DCF $8.70 $15.69 $27.99 72
5Y EBITDA Exit $5.96 $9.90 $16.60 70
All 24 models by family
DCF Models
FCF DCF $9.10 $14.53 $28.98 74
Owner Earnings $7.07 $14.51 $28.86 69
5Y Revenue Exit $4.88 $7.52 $12.23 69
5Y EBITDA Exit $5.96 $9.90 $16.60 70
5Y P/E Exit $7.52 $14.18 $22.56 66
10Y Revenue Exit $6.11 $9.78 $13.87 64
10Y EBITDA Exit $6.92 $11.71 $19.80 64
10Y P/E Exit $7.97 $14.47 $25.22 59
Earnings-Based
Graham-Dodd $2.12 $14.49 $20.31 63
Lynch FV $4.26 $6.08 $7.91 61
PEG = 1.0 $4.26 $6.08 $7.91 57
EPV $2.36 $2.64 $2.87 70
Multiples
P/E Multiple $6.54 $8.73 $10.91 63
P/S Multiple $3.97 $5.30 $6.62 58
P/B Multiple $5.07 $6.76 $8.45 55
EV/EBIT $5.17 $6.75 $8.34 63
EV/EBITDA $4.61 $6.02 $7.42 64
EV/Revenue $2.81 $3.84 $4.88 51
Asset-Based
NCAV (Graham) $0.3200 $0.4800 $0.6000 52
Growth DCF
Growth DCF $8.70 $15.69 $27.99 72
Rev-Margin DCF $4.88 $7.91 $12.34 69
Economic Profit
Residual Income $1.92 $2.53 $3.90 69
ROIC Compounder $2.64 $3.56 $4.27 70
Growth Earnings
Growth-Adj P/E $6.72 $9.60 $12.48 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 63/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 59
How much profit the company makes from its sales and capital
Quality Growth 68
Are margins and returns getting better?
Cashflow 99
Do the profits arrive as real cash?
Financial strength 84
Debt, balance sheet and risk of trouble
Investment 32
Does it invest with discipline instead of growing at any price?
Low Volatility 26
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 16
Distance to the 52-week high, does not count
New shares 34
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 4 officers or directors sold shares worth $5.1M and none bought.

  • SaleDavid BarterChief Financial Officer2× since Jul 8, 2026: 53,868 shares, avg. $15.22$819,672Oct 16, 2026
  • SaleThomas E. HoganAdvisor3× since Jul 2, 2026: 268,200 shares, avg. $15.15$4.1MAug 25, 2026
  • SaleDavid Nicholas GeeChief Marketing Officer5× since May 12, 2026: 12,652 shares, avg. $12.25$154,965Aug 24, 2026
  • SaleMarcus JewellGlobal Chief Revenue Officer4× since May 12, 2026: 26,014 shares, avg. $12.09$314,427Aug 21, 2026

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+18.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.5%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+5.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.8%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 14%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +5.3% a year for the price and +10.9% for the forecasts.
Forecast 2026 (sales)+17.0%
Forecast 2027 (sales)+15.1%
Projected 2028 (sales)+13.5%
Projected 2029 (sales)+11.9%
Projected 2030 (sales)+10.2%

Watch CLBT, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (76 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Note from the team Oct 11, 2026
AI conclusion: Moderate moat potential from margins and a clean balance sheet forms the main strength, yet thin evidence across categories and short-term revenue variability during the cloud transition represent the key weakness.
Main risk: Revenue timing variability during the shift to a consumption-based cloud platform could pressure near-term financial results and scalability realization.
Cellebrite is shifting toward recurring subscriptions and a consumption-based cloud platform. This supports long-term scalability with high margins yet brings short-term revenue timing variability during the transition. Does the growth in annual recurring revenue outweigh the near-term fluctuations from the platform shift, or will the adjustments continue to pressure results?
Join the discussion →

Compare Cellebrite DI with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Software - Infrastructure · 346 stocks

Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 63 · Above median
Fair Value upside +7.2% · Above median
Profitability
Return on equity (12 months) 12.4% · Above median
Return on assets 8.3% · Top 25%
Net margin (12 months) 11.4% · Above median
Operating margin (12 months) 5.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 15.8% · Above median

Valuation Multiplesvs Software - Infrastructure median · lower = cheaper

P/E (12 months) 54.1× · Priciest 25%
P/B 6.50× · Priciest 25%
P/S (12 months) 6.12× · Priciest 25%
Price / free cash flow (fiscal year) 20.2× · Pricier than median
EV/EBITDA 38.5× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)43 · sector 25
FUTURE (revenue growth)79 · sector 60
PAST (return on equity)50 · sector 23
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Software - Infrastructure stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fortinet, Inc FTNT $118.84 $134.76 +13% vs CLBT
Microsoft Corporation MSFT $530.61 $583.67 +10% vs CLBT
Oracle Corporation ORCL $116.10 $111.97 −4% vs CLBT
NetApp, Inc NTAP $169.19 $156.80 −7% vs CLBT
Block, Inc XYZ $85.48 $76.43 −11% vs CLBT
Synopsys, Inc SNPS $450.46 $288.23 −36% vs CLBT
Zscaler, Inc ZS $197.66 $101.45 −49% vs CLBT
Palantir Technologies Inc PLTR $160.38 $42.20 −74% vs CLBT
CrowdStrike Holdings CRWD $216.90 $37.97 −82% vs CLBT
Palo Alto Networks, Inc PANW $313.84 $39.54 −87% vs CLBT

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cellebrite DI: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cellebrite DI Fair Value". https://www.fairvalue-calculator.com/stock/CLBT

Frequently asked questions

Is Cellebrite DI (CLBT) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of $13.34 versus a price of $12.45, about +7% upside (fairly valued).
What is the fair value of CLBT?
Our model-based fair value for Cellebrite DI is $13.34 (as of Nov 3, 2026), built from audited fundamentals. The current price: $12.45.
What is the quality score of CLBT?
Cellebrite DI has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cellebrite DI (CLBT)?
Our model-based price target is the fair value of $13.34 (as of Nov 3, 2026) from 24 valuation models. Cautious scenario $9.34, optimistic scenario $17.35. It is a calculation from audited fundamentals, not an analyst target.
What is the Cellebrite DI stock forecast for 2026?
Our models put fair value at $13.34, about +7% upside versus a price of $12.45 (fairly valued). Cautious scenario $9.34, optimistic scenario $17.35. The calculation is refreshed regularly with new filings.
What is the revenue of Cellebrite DI (CLBT)?
Cellebrite DI reported trailing-twelve-month revenue of about $514M (latest available figure, as of Nov 3, 2026).
What growth is priced into Cellebrite DI (CLBT)?
For today's price to be fair in a discounted-cash-flow model, Cellebrite DI would have to grow free cash flow by +7.8 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.5 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of CLBT use?
Our models discount Cellebrite DI at 10.1 %: a base by market capitalisation (mid), damped by beta 1.13, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cellebrite DI that is +7.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has Cellebrite DI (CLBT) delivered so far?
Over the past 5 years revenue at Cellebrite DI grew +19.5 % a year. The price currently implies free-cash-flow growth of +7.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Cellebrite DI (CLBT) growing?
The median revenue growth in the sector is +11.5 % a year. That is the yardstick for the growth priced into Cellebrite DI (+7.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Cellebrite DI (CLBT)?
The free-cash-flow yield on the price is 4.95 %: that much free cash flow Cellebrite DI produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Cellebrite DI (CLBT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cellebrite DI it is $13.34 per share (as of Nov 3, 2026), against a price of $12.45. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Cellebrite DI stock overvalued or undervalued in 2026?
As of Nov 3, 2026, CLBT trades below its calculated fair value: price $12.45, fair value $13.34, a gap of about +7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLBT?
No. The price is what the market pays today ($12.45); the fair value is what the company's own numbers justify ($13.34). For Cellebrite DI the two are $0.8930 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cellebrite DI worth?
The market values Cellebrite DI at about $3.1B (market capitalisation, as of Nov 3, 2026). Per share that is $12.45; our models calculate a fair value of $13.34 per share.
What do the bullish and bearish scenarios say about CLBT?
Our models span a range for Cellebrite DI: cautious scenario $9.34, base $13.34, optimistic $17.35 per share (as of Nov 3, 2026, price $12.45). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CLBT?
Cellebrite DI trades at a price-to-earnings ratio of 54.1 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $13.34 is built from several models across several years. Other multiples: P/B 6.5, P/S 6.1, EV/EBITDA 38.5.
How solid is the balance sheet of Cellebrite DI (CLBT)?
Balance-sheet figures for Cellebrite DI (as of Nov 3, 2026): return on equity 12.4%. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is CLBT from its 52-week high?
Cellebrite DI trades at $12.45, about 35% below its 52-week high of $19.28 and 19% above the low of $10.44 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $13.34 is for.
Which stocks are comparable to Cellebrite DI?
From the same area (Technology) we also value Microsoft Corporation, Oracle Corporation, Palantir Technologies Inc, Palo Alto Networks, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cellebrite DI stock attractive at the current price?
The data as of Nov 3, 2026: price $12.45, calculated fair value $13.34 (+7%), Quality Score 63/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CLBT calculated?
We run Cellebrite DI through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $13.34 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Cellebrite DI currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cellebrite DI (CLBT)?
The closing price on Nov 6, 2026 was $12.45. Our model-based fair value is $13.34, about +7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cellebrite DI right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($9.34 to $17.35) leaves room in how you read the outcome.

Key figures of Cellebrite DI

How large is the market capitalisation of Cellebrite DI (CLBT)?
The market capitalisation of Cellebrite DI is $3.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cellebrite DI (CLBT)?
The price-to-sales ratio of Cellebrite DI is 6.12 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cellebrite DI (CLBT)?
Earnings per share at Cellebrite DI are $0.2300 (price ÷ EPS = P/E 54.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cellebrite DI (CLBT)?
The net margin of Cellebrite DI is 11.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cellebrite DI (CLBT)?
The return on equity (ROE) of Cellebrite DI is 12.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cellebrite DI (CLBT)?
On an EBIT basis the return on assets of Cellebrite DI is 5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cellebrite DI (CLBT)?
The operating margin of Cellebrite DI is 5.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cellebrite DI (CLBT)?
Revenue at Cellebrite DI is growing +15.8% versus a year earlier (3y avg +20.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cellebrite DI (CLBT)?
Earnings per share at Cellebrite DI are growing −67.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Cellebrite DI (CLBT) hold?
Cellebrite DI holds more cash than debt, $102M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Cellebrite DI in the live analysis

One click puts Cellebrite DI on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.